Axiom Biosciences, a US-headquartered biotech firm developing treatments for infant brain injuries, is planning a primary listing on the Hong Kong Stock Exchange.
The company joins an expanding pipeline of artificial intelligence-powered medical players raising capital in the city, signaling a strategic shift in where specialized biotech firms are seeking public market access.
Axiom’s founder noted that local investors demonstrate greater maturity in handling biotech companies compared to their counterparts on the Nasdaq.
The move highlights a growing appetite among Hong Kong investors for complex biotech narratives.
Axiom’s founder noted that local investors demonstrate greater maturity in handling biotech companies compared to their counterparts on the Nasdaq.
This sentiment suggests that Hong Kong is increasingly viewed as a viable alternative for firms that may face volatility or skepticism in US markets.
The listing comes as other tech and biotech entities also look to Hong Kong for capital.